Validea's guru fundamental report rates ABBVIE INC (ABBV) at 77% using its P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained future growth. While this score is just below the 80% threshold for 'some interest,' ABBV, a large-cap stock in the Biotechnology & Drugs sector, passed key growth metrics including Return on Assets and Cash Flow from Operations. However, the company notably failed criteria related to Capital Expenditures and Research & Development to Assets within the model's framework.
AbbVie Inc. (ABBV) scores 77% under Validea's P/B Growth Investor model, a framework developed by Partha Mohanram to identify high-growth stocks with sustainable upward trajectories. This score places the large-cap biotechnology firm just below the model's 80% threshold for 'some interest'. The analysis reveals a mixed but fundamentally sound profile. ABBV successfully passed crucial criteria related to profitability and operational efficiency, including Return on Assets (ROA), Cash Flow from Operations to Assets, and Sales Variance, indicating strong current financial health. However, the model flagged weaknesses in two key areas for a pharmaceutical company: ABBV failed the tests for Capital Expenditures to Assets and Research and Development to Assets. These failures suggest that, according to this specific quantitative screen, the company's investment in future growth drivers may be suboptimal relative to its asset base, creating a point of concern despite its strong performance on current operational metrics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
